Alcon announced plans to acquire Neurotech Pharmaceuticals, paying $550 million upfront, with additional milestone payments tied to development progress. The deal gives Alcon ownership of an FDA-approved asset as it builds its ophthalmology portfolio. The transaction signals continued consolidation in eye-focused biotech and pharma as large specialty companies seek pipeline depth and differentiated mechanisms. For Neurotech, the move shifts execution leverage to a broader commercialization and regulatory platform under Alcon’s structure. Deal terms reinforce that investors and strategics are still underwriting ophthalmology innovation at scale, particularly when clinical programs can be de-risked by regulatory status and late-stage visibility.